Recently, a core product independently developed by Duochuan Medical (Shenzhen) Co., Ltd.—the DB-T100M electronic single-use bronchoscope catheter—officially received its medical device registration certificate from the Guangdong Medical Products Administration (Registration No.: 粤械注准20252061405).
The approval of this product marks an important milestone for EndoFresh® as it expands into the field of respiratory critical care, providing safe, precise, and comprehensive solutions for clinicians treating critically ill respiratory patients.
Addressing Clinical Pain Points
Setting a New Benchmark for Infection Control
Traditional electronic bronchoscopes often present challenges due to their complex structures, including difficult reprocessing and sterilization, higher risk of cross-infection, and high procurement and maintenance costs.With infection control requirements becoming increasingly stringent in healthcare institutions, clinicians urgently need a bronchoscope solution that can deliver high-definition imaging while fundamentally eliminating the risk of cross-infection.
Key Advantages of EndoFresh® DB-T100M:
- Single-use design eliminates cross-infection risks and is particularly suitable for the diagnosis and treatment of patients infected or colonized with MDRO (multi-drug resistant organisms).
- A portable and highly integrated processor eliminates the need for an external suction pump, enabling procedures with a single processor and scope.
- Built-in workstation supports independent report editing and printing, facilitating bedside diagnosis and treatment.
- Compatible with both gastrointestinal and respiratory endoscopes, meeting the daily diagnostic and treatment needs of intensive care units.
Broad Clinical Applications
Supporting Precise Respiratory Interventions
With the continued implementation of the Healthy China 2030 Initiative and the nationwide advancement of DRG/DIP medical insurance payment reforms, optimizing healthcare resource allocation and strengthening hospital infection control have become key priorities within China’s healthcare system.
Against this backdrop, single-use electronic bronchoscopes, with their rapid response and ready-to-use functionality, fundamentally eliminate the risk of cross-infection caused by inadequate reprocessing. This offers significant advantages in both infection control and clinical efficiency.
The device is particularly effective in preventing the transmission of MDRO (multi-drug resistant organisms), creating an important safeguard against hospital-acquired infections.
It is also worth noting that the project “Single-Use Electronic Bronchoscope for Use in Special Environments such as COVID-19 Infection” has been supported by the Shenzhen Science and Technology Innovation Bureau and received financial support from the Shenzhen Science and Technology Program, further validating its value in special infection control environments.
Project No.: JSGG20200225151708749
EndoFresh® is compatible with both the S2 processor and the portable 2000P processor, enabling multiple scopes with a single system and shared clinical resources.
This not only optimizes equipment configuration and reduces overall costs but also expands the breadth of clinical applications and improves operational efficiency.
The EndoFresh® DB-T100M is designed for clinical diagnosis and treatment of the trachea and bronchi.
It can be widely used in various clinical scenarios, including lung tumor exploration, pathogen detection for infectious diseases, airway foreign body removal, rapid identification of bleeding sites, and preoperative evaluation for tracheal intubation or tracheotomy, providing precise and safe diagnostic and therapeutic support for critically ill respiratory patients.
Looking Ahead to Industry Prospects
Seizing Opportunities for Industry Growth
At present, the single-use bronchoscopy industry is experiencing multiple development opportunities.
At the policy level, China continues to optimize the review and approval process for innovative medical devices, encouraging domestically developed devices with strong clinical value to accelerate market entry.
From a technological perspective, the integration of AI-assisted diagnosis, imaging navigation, and 5G telemedicine with single-use bronchoscopes is continuously expanding their clinical application boundaries.
From a market perspective, the growing demand in primary healthcare institutions and the gradual emergence of overseas market potential are creating broad growth opportunities for domestic enterprises.
The successful approval of EndoFresh® DB-T100M reflects the steady progress of China’s innovative medical device industry under the combined momentum of policy support and technological advancement.
Looking ahead, as healthcare system reforms deepen and clinical needs continue to evolve, domestic medical device companies driven by independent innovation are expected to achieve further breakthroughs in high-end medical equipment and contribute China’s expertise and solutions to global public health.